Conclusion
Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-hospitalization, re-infarction and TLR. It also does not increase the risk of bleeding and cerebrovascular events.